Gsk Share Discussion Threads

[abdullla] 24/11/2017 10:18

This country is its own biggest enemy, by shorting they will kill the value of their family silver like Vodafone and Glaxo, this is the only way they know how to make quick and easy money, imo

[dr biotech] 24/11/2017 10:14

Have to give her time. I think there is decent value here.

[wormhasturned] 24/11/2017 10:06

This will be broken up well before £7 arrives, it’s only a matter of time before activist investors move in here for the kill, and kick that useless woman in to touch!

[tradermichael] 24/11/2017 10:02

LOL.
Current Market Cap £65 billion. Do you really think the company market value will reach £35 billion without several bids wishing to break the company into 3 parts, each on its own is worth >£35 billion

[abdullla] 24/11/2017 09:28

MMs will move the share price to half price just as they did with BT, say £7 imo

[reimomo] 24/11/2017 08:51

Lol shareprice below what it was 20 years ago, not a growth company. This is more like a bond with a yield, but more risk than the GSK corporate bond.

Agreed.

Better options out there.

[tradermichael] 24/11/2017 08:49

Drug research rationalised, 3 big new drug approvals (two of them are potential blockbusters), option to buy Novartis Consumer Health stake in their JV.

[montyhedge] 24/11/2017 08:46

Shareprice May bounce if CEO said not bidding for Pfizer consumer division, bid equals dividend cut in investors eyes.Lol shareprice below what it was 20 years ago, not a growth company. This is more like a bond with a yield, but more risk than the GSK corporate bond.

[reimomo] 24/11/2017 08:39

Growth is very weak. Q3 expectations missed. More spent on divvy than generated. Something has to give...

[woodhawk] 23/11/2017 12:57

I don't see much downside from here - there's a hell of a lot of nebulous 'bad news' in the price (likely to evaporate at any time, imo) and if the share price remains at this level, or goes lower, then I reckon GSK is a prime takeover-target - especially so with the £ so weak. Anyway for the time being, I'll happily collect 6+% divi pa instead of a derisory 1.2% in the bank.

[reimomo] 23/11/2017 11:17

Don't think the lack of a bid will mean the divi is safe.

Huge debt and poor top line growth means cutting costs the only solution.

[montyhedge] 23/11/2017 10:46

TraderWith IMM everyone assumes it will get approval, then a bid. If successful great, no guarantee of a bid, then I assume they would have to have a fund raise for next step. In my view they have run high enough for now.

[montyhedge] 23/11/2017 10:36

The market ignoring any news, but focusing on any bid GSK may make. CEO let the cat out the bag with her comments, bid equals divi cut in some investors eyes. How will they pay for a bid?

[tradermichael] 23/11/2017 09:58

Although IMM's share price has doubled in recent months with this hype (?), it seems odd that their projected success has not made a much larger difference.

[woodhawk] 23/11/2017 09:19

So what's not to like? News gets better and you can buy cheaper and cheaper! Won't last long.

[spoole5] 23/11/2017 08:13

newsflow seems irrelevant here now

[tradermichael] 23/11/2017 08:10

GlaxoSmithKline PLC (GSK.LN) said Thursday that it has filed a supplemental new drug application with the U.S. Food and Drug Administration to support an expanded label for its inhaler Trelegy Ellipta.

The application is to expand the treatment's indication so that physicians can use it to treat chronic obstructive pulmonary disease patients who require triple therapy, the company said.

The pharmaceutical company submitted data from its impact study which show the efficacy and safety of the treatment in a single inhaler, it said.

The treatment was approved for use in the U.S. in September for the long-term, once-daily, treatment of chronic obstructive pulmonary disease patients and, if approved, the supplemental new drug application would broaden this indication.

[masurenguy] 23/11/2017 07:54

Green light for HIV pill is tonic for Glaxo chief

The world’s first two-drug regimen to treat HIV has won approval from US regulators. The recommendation from the Food and Drug Administration for the once-daily pill is an important early milestone for Emma Walmsley, Glaxosmithkline’s chief executive, who had made it one of three key drugs when she took charge in April. Approval for the two others, a shingles vaccine and a three-in-one inhaler for chronic lung disease, were approved in the past two months, boosting Glaxosmithkline’s attempts to replenish declining sales from its blockbuster Advair inhaler, which faces competition from generic rivals.

Complete article:

[bracke] 22/11/2017 15:44

From a charting perspective there is nothing to suggest that the fall is complete and a rise is about to begin. Maybe one of the dashed line below will give support.

GSK DAILY

[mj19] 22/11/2017 15:36

And that was the end of that...

[philanderer] 22/11/2017 13:50

Guardian newspaper

"Is the NHS being taken for a ride on drug prices? We need to know"

The competition watchdog is investigating, but we need a wider inquiry into pharmaceutical firms’ practices

[mj19] 22/11/2017 13:41

I said don't look...